Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2020
- $ 2000
- May 2024
- 152 pages
Ampligen is under development f or the treatment of pancreatic cancer, breast cancer, metastatic triple negative breast cancer, colorectal cancer, ovarian cancer, peritoneal cancer, metastatic melanoma, renal cell carcinoma, non-small cell lung cancer, bladder cancer, prostate cancer, thermal injury and Ebola viral inf ections, chronic f atigue syndrome, West Nile virus inf ection, Zika virus inf ections, HIV inf ections and H5N1, H7N9 inf luenza infections, severe acute respiratory syndrome, coronavirus disease 2019 (COVID-##) and pandemic inf luenza. [...] It is in Phase I/II stage of development f or recurrent epithelial ovarian cancer and peritoneal cancer (second line therapy), metastatic melanoma, renal-cell cancer, ovarian cancer, peritoneal cancer in the U.S and breast cancer globally. [...] Phase I/ II study of Ampligen plus Intron A in intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer.